Atropine Pediatric Dose — Resuscitation
Atropine is a parasympatholytic (anticholinergic) agent that competitively antagonizes acetylcholine at muscarinic receptors, resulting in increased heart rate and improved atrioventricular conduction. In pediatric resuscitation, it is primarily used to treat hemodynamically significant bradycardia, particularly when vagal tone or cholinergic excess is the underlying cause.
Pediatric Dosing
- IV: 0.02 mg/kg IV — Minimum 0.1 mg; Maximum 1 mg per dose
- IM / Endotracheal (ET): 0.04 mg/kg IM or ET
The minimum dose of 0.1 mg IV is enforced regardless of calculated weight-based dose to avoid paradoxical bradycardia, which can occur with very small doses. Consult institutional protocol regarding repeat dosing intervals.
Worked example: For a 10 kg child: 10 × 0.02 mg/kg = 0.2 mg IV (within the 0.1–1 mg range). For a 3 kg infant: calculated dose = 0.06 mg — administer the minimum 0.1 mg IV.
Indications and Clinical Context
Atropine is indicated in pediatric resuscitation for the management of symptomatic bradycardia associated with poor perfusion that is suspected to be vagally mediated or related to cholinergic excess (e.g., following succinylcholine administration, airway suctioning, or organophosphate toxicity). Per PALS guidelines, atropine is considered after epinephrine for bradycardia with a pulse when the rhythm is not responsive to oxygenation and ventilation alone.
It is also administered via the intramuscular or endotracheal route when IV/IO access is unavailable, though IV or IO access is strongly preferred in resuscitation settings due to more reliable pharmacokinetics.
Administration and Monitoring
Administer IV doses as a rapid bolus to maximize vagolytic effect; slow infusion may paradoxically worsen bradycardia. The endotracheal dose (0.04 mg/kg) should be diluted in 3–5 mL of normal saline and followed by several positive-pressure ventilations to enhance absorption, though absorption via ET route is less predictable than IV/IO. Enforce the minimum dose of 0.1 mg for all IV administrations.
- Monitor continuous cardiac rhythm and heart rate response following administration.
- Observe for anticholinergic adverse effects: tachycardia, flushing, urinary retention, dry secretions, and mydriasis.
- Use with caution in patients with narrow-angle glaucoma or obstructive uropathy.
- For dosing in very low-weight infants or unusual clinical scenarios, consult institutional protocol.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.